NEW ZEALAND GAZETTE, No. 136

1 SEPTEMBER 2011

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

(a) must state in full the reasons for making the submission; and

(b) may state any decision sought on that application; and

(c) must be received by the director-general no later than 30 working days after the date of notification in the New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.

The following address is:

(a) where submissions on this application are to be sent; and

(b) where requests for copies of the public information relating to the application can be sent; and

(c) where public information relating to the application can be viewed; and

(d) the director-general’s address for service:

ACVM Group, Ministry of Agriculture and Forestry, Pastoral House, Level 11, 25 The Terrace, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140.

The applicant’s address for service is:

Novartis New Zealand Limited, Building G, 5 Orbit Drive, Rosedale, Auckland 0632. Postal Address: Private Bag 65904, Mairangi Bay, Auckland 0754.

Dated at Wellington this 25th day of August 2011.

MAREE ZINZLEY, Manager (Approvals Operations), Ministry of Agriculture and Forestry (acting under delegated authority).

go6005

Notice of Application to Register a Trade Name Product (Notice No. 1745)

Maree Zinzley, Manager (Approvals Operations) of the Ministry of Agriculture and Forestry (MAF) acting under delegated authority from the Director-General of MAF, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 ("the Act"), that the following application has been made to register a trade name product under section 9(1) of the Act:

Trade Name: Onsior Injection for Cats and Dogs

Reference: A010702

Active Ingredient and Concentration:

Robenacoxib 20mg/mL

Formulation Type: Injection

General Use Claims: For the control of pain and inflammation associated with orthopaedic or soft tissue surgery in dogs and soft tissue surgery in cats.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

(a) must state in full the reasons for making the submission; and

(b) may state any decision sought on that application; and

(c) must be received by the director-general no later than 30 working days after the date of notification in the New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.

The following address is:

(a) where submissions on this application are to be sent; and

(b) where requests for copies of the public information relating to the application can be sent; and

(c) where public information relating to the application can be viewed; and

(d) the director-general’s address for service:

ACVM Group, Ministry of Agriculture and Forestry, Pastoral House, Level 11, 25 The Terrace, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140.

The applicant’s address for service is:

Novartis New Zealand Limited, Building G, 5 Orbit Drive, Rosedale, Auckland 0632. Postal Address: Private Bag 65904, Mairangi Bay, Auckland 0754.

Dated at Wellington this 25th day of August 2011.

MAREE ZINZLEY, Manager (Approvals Operations), Ministry of Agriculture and Forestry (acting under delegated authority).

go6006

Notice of Application to Register a Trade Name Product (Notice No. 1748)

Maree Zinzley, Manager (Approvals Operations) of the Ministry of Agriculture and Forestry (MAF) acting under delegated authority from the Director-General of MAF, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 ("the Act"), that the following application has been made to register a trade name product under section 9(1) of the Act:

Trade Name: Onsior 5mg Tablets for Dogs

Reference: A010704

Active Ingredient and Concentration:

Each tablet contains:

Robenacoxib 5mg

Formulation Type: Tablet

General Use Claims: For the control of pain and inflammation associated with chronic osteoarthritis or orthopaedic or soft tissue surgery in dogs.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

(a) must state in full the reasons for making the submission; and

(b) may state any decision sought on that application; and

(c) must be received by the director-general no later than 30 working days after the date of notification in the New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.

The following address is:

(a) where submissions on this application are to be sent; and

(b) where requests for copies of the public information relating to the application can be sent; and

(c) where public information relating to the application can be viewed; and